NDAORALCAPSULE
Approved
Oct 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
7/8 — Comprehensive
AKYNZEO (netupitant and palonosetron) by Helsinn is serotonin 3 receptor antagonists [moa]. Approved for chemotherapy-induced nausea and vomiting. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKYNZEO is a fixed-dose combination of netupitant (NK1 antagonist) and palonosetron (5-HT3 antagonist) in oral capsule form for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). It is indicated as adjunct to dexamethasone in adults receiving highly emetogenic cancer chemotherapy. The dual mechanism targets both substance P and serotonin pathways to prevent CINV across acute and delayed phases.
$5MPart D
PeakStable
9.4 years to LOEAKYNZEO remains in peak lifecycle phase with stable but modest Part D spending (~3,836 claims in 2023), suggesting a stable market position with limited growth trajectory for commercial expansion teams.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Indications (1)
Clinical Trials (9)
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
Started Feb 2021
414 enrolled
Chemotherapy-induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
Started Oct 2018
207 enrolled
Chemotherapy-Induced Nausea and Vomiting
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Started Sep 2018
80 enrolled
Chemotherapy-induced Nausea and VomitingAdverse EventCervical Cancer
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
Started Aug 2017
67 enrolled
Chemotherapy-induced Nausea and Vomiting (CINV)
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Started May 2017
53 enrolled
Malignant NeoplasmNauseaVomiting
Worked on AKYNZEO at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.